NCT06340516View on ClinicalTrials.gov

NT-proBNP to Assess Trastuzumab-induced Cardiotoxicity

NARecruitingINTERVENTIONAL
Enrollment

700

Participants

Timeline

Start Date

March 14, 2024

Primary Completion Date

March 14, 2029

Study Completion Date

March 14, 2029

Conditions
CardiotoxicityBreast CancerTreatment Side Effects
Interventions
DIAGNOSTIC_TEST

Plasma NT-proBNP

Replacement of measurement of plasma NT-proBNP instead of ECHO/MUGA at 6 months and 12 months of trastuzumab treatment to assess cardiotoxicity

Trial Locations (1)

432 45

RECRUITING

Jubileumskliniken, Sahlgrenska University Hospital, Gothenburg

All Listed Sponsors
lead

Vastra Gotaland Region

OTHER_GOV